Patient characteristics
| . | n (%) . |
|---|---|
| N | 18 |
| Age, median (range), y | 63 (43-88) |
| Male | 4 (22) |
| PS, ≥2 | 5 (28) |
| LDH, above UNL | 8 (44) |
| Disease | |
| PCNSL | 16 (89) |
| SCNSL | 2 (11) |
| Hans criteria | |
| GCB | 4 (22) |
| Non-GCB | 10 (56) |
| Unknown | 4 (22) |
| Time from diagnosis, median (range), mo | 14.9 (3.8-193) |
| Previous lines of treatment, median (range) | 2 (1-4) |
| Previous transplant | 3 (17) |
| Previous CAR T-cell therapy | 2 (11) |
| Refractory to previous treatment | 10 (55) |
| . | n (%) . |
|---|---|
| N | 18 |
| Age, median (range), y | 63 (43-88) |
| Male | 4 (22) |
| PS, ≥2 | 5 (28) |
| LDH, above UNL | 8 (44) |
| Disease | |
| PCNSL | 16 (89) |
| SCNSL | 2 (11) |
| Hans criteria | |
| GCB | 4 (22) |
| Non-GCB | 10 (56) |
| Unknown | 4 (22) |
| Time from diagnosis, median (range), mo | 14.9 (3.8-193) |
| Previous lines of treatment, median (range) | 2 (1-4) |
| Previous transplant | 3 (17) |
| Previous CAR T-cell therapy | 2 (11) |
| Refractory to previous treatment | 10 (55) |
CAR, chimeric antigen receptor; LDH, lactate dehydrogenase; PS, performance status; UNL, upper normal limit.